Healthcare Marketing

BEST SINGLE PROFESSIONAL PRINT ADVERTISEMENT


A single print ad for a prescription drug, medical product or service appearing in any medical journal or periodical. OTC products are not permitted in this category.

GOLD

NTM Isn't Waiting Agency: Area 23 Client: Insmed

NTM is an orphan respiratory disease that most often afflicts patients with serious lung damage from other conditions such as COPD or emphysema.

"Research indicated that pulmonologists deprioritized treating NTM because they didn't understand the extent and severity of the damage that results [when NTM is untreated]," an Area 23



representative explained.
"Our goal was ... to instill in
them a sense of extreme
urgency to treat—that

every day they wait, more irreversible damage is being done."

The brilliant creative shows a pair of wooden lungs being attacked and rapidly eroded by termites to illustrate the dire consequences of allowing NTM to run unabated.

Judges admired the work, describing it as "dramatic" and praising the compel-

ling imagery.

"Termite-riddled lungs are a powerful warning," one judge said.

The ad first ran in American Thoracic Society Daily during the week of the ATS congress in May 2014. It, as well as all elements of the overall campaign, drove pulmonologists to a dedicated website to learn more.

Website results included visits from 38 countries, a 35% retention rate and an average of time 3:24 spent on the site. The agency also reported that nearly 10% of the target demographic registered on the site in the first month alone.

FINALISTS

- Anderson DDB Health & Lifestyle and GSK for Tattoo
- Area 23 and Insmed for NTM Isn't Waiting
- CDM New York and Salix Pharmaceuticals for Xifaxan 550 mg: Lost Forever
- The CementBloc and Novartis for Bexsero: Something's Missing
- McCann Echo and Galderma for Soolantra: Introducing a Tough Topical Journal Ad

SILVER

Soolantra: Introducing a Tough Topical Journal Ad Agency: McCann Echo Client: Galderma

Judges unanimously applauded the creative approach of personifying Galderma's Soolantra as a superhero type who, poised on a fingertip, stares down the frightened, red-faced rosacea lesions it treats.

"A very graphical



approach," said one judge. "Well done."

Results included 9.7% market share in the dermatology segment after only eight weeks in the US market.